<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04691167</url>
  </required_header>
  <id_info>
    <org_study_id>r-TMS</org_study_id>
    <nct_id>NCT04691167</nct_id>
  </id_info>
  <brief_title>the Role of Repetitive Trans Cranial-magnetic Stimulation in Craving Reduction Among Opioid Use Disorder Patients</brief_title>
  <official_title>The Role of Repetitive Trans Cranial-magnetic Stimulation in Craving Reduction Among Opioid Use Disorder Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Repetitive Trans-cranial Magnetic Stimulation (rTMS) is a relatively safe and non-invasive&#xD;
      method to modulate neuronal activity; rTMS uses alternating magnetic fields in a certain&#xD;
      frequency to induce an electric current in the underlying brain tissue.&#xD;
&#xD;
      Administering high frequency rTMS to the left dorsolateral prefrontal cortex is possible to&#xD;
      increase brain activity in the stimulated area and to change brain activity in associated&#xD;
      regions that are part of the same neural circuit which may reduce craving.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>single blind sham-controlled randomized clinical trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>craving severity</measure>
    <time_frame>6 weeks</time_frame>
    <description>measure severity of drug craving using craving severity scale, the scale is called brief substance craving scale. a higher outcome is a worse result</description>
  </primary_outcome>
  <primary_outcome>
    <measure>heroin craving</measure>
    <time_frame>6 weeks</time_frame>
    <description>using the heroin craving questionnaire, a higher score indicates a worse outcome</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Substance Use Disorders</condition>
  <arm_group>
    <arm_group_label>group 1, Active intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2, sham controlled group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>repetitive trans magnetic stimulation</intervention_name>
    <description>Repetitive Trans-cranial Magnetic Stimulation (rTMS) is a relatively safe and non-invasive method to modulate neuronal activity; rTMS uses alternating magnetic fields in a certain frequency to induce an electric current in the underlying brain tissue.</description>
    <arm_group_label>group 1, Active intervention group</arm_group_label>
    <arm_group_label>group 2, sham controlled group</arm_group_label>
    <other_name>r-TMS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age range: 18-45 years old&#xD;
&#xD;
          2. Gender: males&#xD;
&#xD;
          3. Opioid Use disorder according to the DSM-5 (early abstinence starting 1 week up to 1&#xD;
             month).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of other serious mental illness (e.g.; psychotic disorders, bipolar affective&#xD;
             disorder, depression with psychotic features).&#xD;
&#xD;
          2. Patients with any other serious medical illness.&#xD;
&#xD;
          3. Previous treatment with repetitive Trans- cranial magnetic stimulation.&#xD;
&#xD;
          4. Patients with contraindications to rTMS as cardiac patient with pacemaker.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>amany haroun, BCH, MD</last_name>
    <role>Study Chair</role>
    <affiliation>professor at ain shams university, faculty of medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noha Ahmed saad, bch,MS</last_name>
    <phone>01227666923</phone>
    <phone_ext>002</phone_ext>
    <email>nohaahmedsaad@gmail.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>October 31, 2021</last_update_submitted>
  <last_update_submitted_qc>October 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Noha Ahmed Saad</investigator_full_name>
    <investigator_title>assistant lecturer of Neuropsychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

